전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved55 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 1

Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor, Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#BreastNeoplasms+2
Trials 1Status Active
CGTLimited DatastaleIRCCS Azienda Ospedaliero-Unive…Preclinical

Alloreactive NK cell infusion (Alloreactive NK cell infusion)

Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia in Remissio

#AdultAcuteMyeloidLeukemiainRemis#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous B7-H3 CAR T (Autologous B7-H3 CAR T)

Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#monoclonal-antibody#NeuroendocrineTumors+1
Trials 1Status Active
ADCLimited DatastaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages)

AL Amyloidosis; Amyloidosis · AL Amyloidosis

#ALAmyloidosis#ADC#Phase2#antibody-drug-conjugate#Amyloidosis+1
Trials 1Status Recruiting
AntibodyLimited DatastaleInternational Extranodal Lympho…Phase 2

Bendamustine and Rituximab (Bendamustine and Rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#International
Trials 1Status Active
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody)

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#IneligibleOrRefusedTransplantPat+1
Trials 1Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

CAR-T Re-treatment (CAR-T Re-treatment)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing Friendship HospitalPhase 1

CD207 CAR-T cells (CD207 CAR-T cells)

Langerhans Cell Histiocytosis · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChimeric TherapeuticsPhase 2

CHM-2101 CAR-T cells (CHM-2101 CAR-T cells)

Neuroendocrine Tumors; Colorectal Cancer · Neuroendocrine Tumors

#NeuroendocrineTumors#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleCedars-Sinai Medical CenterPhase 1

Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab (Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#Antibody#Phase1#monoclonal-antibody#GlioblastomaMultiforme+1
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 3

trastuzumab (Herceptin, Endocrine therapy combined with trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#monoclonal-antibody#Sun
Trials 1Status Active
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
CGTLimited DatastaleAMERICAN ORGAN TRANSPLANT AND C…Phase 2

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

End-Stage Renal Disease; End Stage Renal Disease on Dialysis · End-Stage Renal Disease

#End-StageRenalDisease#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChildren's Oncology GroupPhase 1

HER2 Specific CAR T Cell (HER2 Specific CAR T Cell)

Ependymoma · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-C182A cells (LCAR-C182A cells)

Gastric Cancer; Pancreatic Ductal Adenocarcinoma · Gastric Cancer

#GastricCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-C18S cells (LCAR-C18S cells)

Solid Tumors, Adult · Solid Tumors, Adult

#SolidTumorsAdult#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-G08 cells (LCAR-G08 cells)

Advanced Gastrointestinal Tumors · Advanced Gastrointestinal Tumors

#AdvancedGastrointestinalTumors#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued

2 / 3 pages

← PreviousNext →